Celonic

Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.

eppendorf-new_CDMO115x65V2

For CDMOs, flexible upstream platforms can help streamline process ­development while maintaining reproducibility and continuity across scales.

Justyna Adamczyk, 
Associate VP Integrated MS&T at Rezon Bio

Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.

Monarch_Advertorial_202502_EU

Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.

Professor Jacob George, Chief Medical and Scientific Officer at the MHRA presenting his keynote speech at Phacilitate Advanced Therapies Europe, 2026

Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.

Ute Kilger

In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation of the description is an extensive and very costly writing exercise. There was inconsistent case law of the Boards of Appeal (TBoA) on whether and to what extent said adaptation is necessary. The Enlarged Board of Appeal (EBoA) has now decided, and it changes for the worse for the practitioner.

Ponchi Kantt-Neaz, Global Executive Business Director 3PBIOVIAN

The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.

indivumed_beide_960x540-705x397

With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.

image

3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.

The Basel region is one of the world’s leading life-science clusters. ­Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the industry continues to grow, the demand for ­scalable laboratory and office environments within this innovation ecosystem is increasing.